NUVISAN

DRUG DISCOVERY

Digital Life Sciences

www.nuvisan.com

DIGITAL LIFE SCIENCE EXPERTISE

Bioinformatics

- *In silico* target prediction
- Omics Data analysis & interpretation

10X GENOMICS CERTIFIED SERVICE PROVIDER

Single Cell Gene Expression &
Single Cell Immune Profiling

MOLECULAR MODELING

support from early druggability to lead optimization campaigns

★★★★★

STATE-OF-THE-ART

Data Science Technology under ***FAIR Data Principles***



3 million compound library with **1 billion *in vitro / vivo* data points**

High throughput screening,
virtual screening
& data mining

QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) & MACHINE LEARNING (ML)

MODEL DEVELOPMENT FOR ACTIVITY,
DMPK & PHYSCHEM PROPERTY PREDICTION

NUVISAN

Our Digital Science For Drug Discovery

At NUVISAN, we believe that data is at the very core of the drug discovery process. Our team of digital experts works closely with our clients to implement the most suitable strategy for a new target identification, hit finding, or lead optimization program. With decades of pharma expertise, NUVISAN uses computer-aided drug design approaches to deliver the next blockbuster drugs by leveraging the latest digital technologies together with the in-house Life Science Database to accelerate and guide scientific decisions. We offer:

- A **highly multidisciplinary team** collaborating across the functions, using state-of-the art digital technologies, committed to the FAIR data principles
- Experienced partner for the **omics data analysis and interpretation**, as well as bioinformatics expertise for *in silico* target and indication space evaluation
- Our Life Science Database contains **3 million well-characterized compounds** associated with ~1 billion *in vitro* and *in vivo* data points
- We apply molecular modeling to support projects **from early druggability analysis and hit finding**, to hit-to-lead and lead optimization campaigns
- Fine analysis of chemical matters, including **QSAR and ML/AI model development** for different ADME endpoints is supported by our cheminformatics team



From Target Identification to Novel Chemical Matter

Bioinformatics

We facilitate integrated design, implementation, and data analysis for target validation or biomarker discovery by employing state-of-the-art data science methods including data mining, multivariate statistics, data visualization, and machine learning. Application fields include:

- Transcriptomics, genomics, and epigenomics
- High-content cellular assays
- *In silico* target and indication space evaluation

Cheminformatics & Machine Learning

Our data platform enables efficient screening, prediction of efficacy and safety, and design/optimization of new chemical series. Get ahead of competition with cutting-edge approaches for:

- Mining Life Science Database
- QSAR modeling
- ML physchem and DMPK endpoint prediction
- AI-powered de novo generative molecular design

NUVISAN



Data Driven Molecule Generation

Life Science Database (LSDB)

NUVISAN'S proprietary LSDB is built on decades of pharma research and contains 3 million unique molecules associated with ~1 billion experimental data points covering biological activity, physchem, DMPK endpoints and more. We rely on LSDB for:

- Analyzing data for hits identified through high-throughput screens
- Data mining and virtual screening approaches

Molecular Modeling

Accelerate projects from hit finding to lead optimization by predicting the behavior of potential drug candidates & optimize their properties before synthesis & testing with cutting-edge computer-aided drug design techniques:

- Binding pocket identification and druggability assessment
- Ligand- and structure-based virtual screening
- Docking and molecular dynamics simulations
- Multi-parameter optimization in Design-Make-Test-Analyze (DMTA) cycles

NUVISAN

The Science CRO - From Target to Patient

The NUVISAN group is a contract research and development and manufacturing organization (CRO/CDMO) with six sites in Germany and France as well as local experts situated in Latin America.

We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient.

Thanks to more than 40 years of experience and about 1,000 employees (incl. > 70 % industry experienced scientists and lab professionals), we know how to discover, develop, and bring the next generation medicines to market. At the same time, our scientists understand that every project is different. With a flexible and innovative approach and transparent communication, our teams are passionate about closely collaborating with you to adapt to your individual needs.



Contact us

Dr. Dusan Petrovic
Head of Digital Life Sciences
dusan.petrovic@nuvisan.com

Dr. Christoph Sachse
VP Business Development
christoph.sachse@nuvisan.com

NUVISAN ICB GmbH
Muellerstr. 178
13353 Berlin, Germany

Web: www.nuvisan.com
Email: hello@nuvisan.com
LinkedIn: company/nuvisan